Yuting Sun
5PUBLICATIONS
51CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Sep 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul
|Dec 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.Alexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul
|Dec 19, 2020
Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers.Yu-Hsi Lin, Nikunj Satani, Naima Hammoudi
|Nov 24, 2020
An enolase inhibitor for the targeted treatment of ENO1-deleted cancers.Yu-Hsi Lin, Nikunj Satani, Naima Hammoudi
|Sep 15, 2020
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.Yuting Sun, Brooke A Meyers, Barbara Czako
Pageof 1
Frequent Collaborators
2 joint publications
Federica Pisaneschi
2 joint publications
Benjamin Besse
2 joint publications
Joshua C Horan
2 joint publications
Xiaobo Wang
2 joint publications
Anupong Tangpeerachaikul
2 joint publications
David Maxwell
2 joint publications
Alexander Drilon
2 joint publications
Cong-Dat Pham
2 joint publications
Nikunj Satani
2 joint publications
Yu-Hsi Lin
